Novartis: Follow The (Belgian) Yellow Brick Road – Seeking Alpha
|
Novartis: Follow The (Belgian) Yellow Brick Road
Seeking Alpha We should not forget, however, that Novartis is developing CTL019 (tisagenlecleucel-T), a novel chimeric antigen receptor (CAR) T-cell therapy for pediatric and young adult patients with relapsed and refractory with B-cell acute lymphoblastic leukemia … |
